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Adenosine receptors belong to Class A, also termed rhodopsin-like,
G protein-coupled receptors (GPCRs). Four subtypes of adenosine
receptors have been identiﬁed: A1, A2A, A2B and A3. Activation of A1
and A3 adenosine receptors leads to an inhibition of the enzyme
adenylate cyclase mediated by an inhibitory G protein (Gi), whereas
A2A and A2B receptors, once activated, cause a Gs-mediated stimula-
tion of this enzyme [1].
Many representatives of Class A receptors, among them adenosine
receptors, have been shown to be allosterically regulated. An allosteric
site is a ligand binding site on the protein that is distinct from the
orthosteric primary ligand binding site to which ligands such as
endogenous adenosine and synthetic derivatives thereof bind. The
binding of modulators causes conformational changes of the receptor,
which may affect the binding of the orthosteric ligand.
An allosteric modulator does not have any activity by itself, but it
‘needs’ the orthosteric ligand (often the endogenous hormone or
neurotransmitter) to show its action. The allosteric modulatory
character of compounds is, however, not always clear-cut. Some
small-molecule agonists also display allosteric properties. An ago-
allostericmodulator e.g. functions both as an agonist on its own and as
allosteric modulator of the efﬁcacy and/or the potency of the
orthosteric ligand. A ligand that is able to mediate receptor activation
on its own by binding to a recognition domain of the receptor
macromolecule that is distinct from the primary site is called an
allosteric agonist. True allosteric modulators increase or decrease the
action of an agonist or an antagonist by combining with the allosteric
site on the receptor macromolecule [2]. The overall pharmacology
invoked by an allosteric modulator is closer to physiology than is
possible with most of today's drugs, i.e. synthetic orthosteric ligands
(see Fig. 1, for the effect of an allosteric enhancer).
Allosteric modulation of established drug targets such as GPCRs
has fueled an intensive quest for new classes of lead compoundsFig. 1. Allosteric modulators may either increase or decrease the effect of an agonist or
an antagonist. An allosteric enhancer can be a more physiologic alternative to synthetic
agonists (b, c). An allosteric enhancer can only act in the presence of an (endogenous)
agonist. It mimics the duration and intensity of action of hormone or neurotransmitter
(a) much better than a synthetic agonist (c). This combined action of two compounds
(i.e. agonist and enhancer) might also induce selectivity of drug action.different from ‘classic’ agonists and antagonists. This has been the
subject of several recent reviews [3–7].
Since adenosine receptors were among the ﬁrst GPCRs discovered
to be allosterically regulated, these receptors have often been
reviewed too [8–11]. The aim of the present review is to collect the
latest developments in this fascinating ﬁeld for all four subtypes of
adenosine receptors. The chemical classes of allosteric ligands and
their structure–activity/afﬁnity relationships will be discussed next to
hypotheses regarding the putative binding site of the modulators.
1.1. A1 adenosine receptors
Baraldi et al have published a comprehensive review of allosteric
modulators of A1 adenosine receptors [10]. As a follow-up we will
provide an overview of the “historical” as well as new allosteric
modulators for A1 adenosine receptors.
The ﬁrst allosteric modulators of the A1 adenosine receptor were
introduced by Bruns et al. in 1990 [12,13]. Three compounds, PD
71,605, PD 81,723 and PD 117,975 were studied in detail (see Fig. 2).
These chemical structures belonged to the Parke-Davis compound
library, and were originally used as intermediates in the synthesis of
benzodiazepine-like compounds [14]. The discovery of their allosteric
enhancing character was a serendipitous ﬁnding. While screening the
library in a radioligand binding assay, the authors observed PD 71,605,
PD 81,723 and PD117,975 to increase rather than decrease the binding
of the agonist radioligand [3H]N6-cyclohexyladenosine to A1 adeno-
sine receptors in rat brainmembranes. These so-called enhancerswere
next shown to slow the dissociation of the agonist [3H]N6-cyclohex-
yladenosine from the A1 receptor, indicating an allosteric mechanism
of action. These compounds also appeared to behave as competitive
antagonists at the same receptor. Therefore the concentration range
within which these compounds enhance the effects of agonists is
limited, in the 1–10 μM range. PD 81,723 was one of the more potent
compounds with the best ratio of enhancing to antagonistic action. PD
81,723 has been thoroughly studied over the years by many different
research groups and inmany different formats, and it thus became the
reference allosteric modulator of A1 adenosine receptors. It has been
extensively modiﬁed structurally [12,13].
A series of 2-amino-3-benzoylthiophenes with PD 81,723 as the
starting point was synthesized by Van der Klein et al. [15]. Compounds
1–3 (Fig. 2) proved to be more potent enhancers than PD 81,723 with
comparable antagonistic activity. The biological assays were carried
out on membranes of rat brain cortex, the enhancing activity was
measured at 10 μM of test compound. For compound 1 the en-
hancementwas 122%, for compound 2 123% and for compound 3 151%
compared to that of PD 81,723 (100%).
In this class of 2-amino-3-benzoylthiophene derivatives lipophilic
benzoyl (3-CF3, 3,4 Cl or 4-t-butyl) substitution and thiophene 4-alkyl
substitution favored allosteric enhancing activity. However, bulky
substitution at the 5-position favored antagonistic properties, which
rendered the separation of these two activities in these structures
possible (see Figs. 2 and 3) [16].
Baraldi et al. also developed a series of PD 81,723 analogues.
Compounds 2, 4 and 5 (Fig. 2) proved to be nearly as efﬁcacious as
(effect on Emax) and more potent (effect on EC50) than PD 81,723 and
caused a signiﬁcant reduction of the cAMP content of CHO cells
expressing human A1 receptors (CHO:hA1) at a concentration of
0.1 μM [17]. In a more extensive study a large number of 2-amino-3-
naphthoylthiophenes were investigated by the same authors [18].
Compound 6 was the most active, increasing agonist binding
to CHO: hA1, human brain and rat cortex membranes by 149%, 43%
and 27% (51%, 15% and 22% for PD 81,723). Among the 4,5,6,7-
tetrahydrothieno[2,3-c]pyridine derivatives only compound 7
showed signiﬁcant allosteric enhancer activity. A series of 2-amino-
3-heteroarylthiophenes were also synthesized, revealing that com-
pounds 8–11 behaved as allosteric enhancers in the human A1
Fig. 2. 2-Amino-3-substituted thiophene derivatives as allosteric modulators for A1 adenosine receptors.
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position of the thiophene ring, as in PD 81,723, with a 2- or 3-thienyl
moiety maintained the enhancing activity [19]. Thieno[2,3-c]pyridine
derivatives were obtained by the Baraldi group by means of
microwave-assisted synthesis. Compound 12 showed activity compa-
rablewith that of PD81,723 (Fig. 2) [20]. In a later study 2-amino-3-(4-
chlorobenzoyl)-4-[4-(alkyl/aryl)piperazin-yl]thiophene derivatives
were described as allosteric enhancers of the A1 adenosine receptor.
Among them the 4-chlorophenyl 13 and the 4-triﬂuoromethyl 14
derivatives proved to be the most active compounds in binding and
functional cAMP studies (see Fig. 3). In [3H]CCPA saturation binding
experiments the Bmax shift (fold increase)was 1.3 for PD81,723, 7.0 for
compound 13 and 7.7 for compound 14, while in [3H]DPCPX com-
petition binding experiments the CCPA Ki shift (fold increase) was 1.7
for PD81,723, 5.6 for compound 13, and 6.3 for compound 14 [21].A systematic survey of the PD 81,723 lead structure was also
performed by Tranberg et al. The 3-OMe derivative 15 had high
enhancing activity and relatively low antagonistic potency, 99% and
13% at 100 μM [22]. The same research group showed that chemical
structures more different from the prototypic PD 81,723 were
allosteric enhancers too [23]. The allosteric enhancing activity (AE)
score of PD 81,723was 19% and it served as a standard for comparison.
For compound 16 it was 48% and for the 3-(1-naphthoyl) substituted
compound 17 52%. Compounds 18 and 19 seemed to be more potent
with scores of 91% and 80%, respectively (Fig. 3). In this study
allosteric enhancing activity was assessed in a slightly different way
and consisted of three phases: (1) binding to equilibrium of the
agonist 125I-ABA to the A1 adenosine receptor, (2) addition of the
putative allosteric enhancer, and (3) dissociation of the complex by
adding a combination of an A1 adenosine receptor antagonist and
Fig. 3. Recently published 2-amino-3-substituted thiophene derivatives as allosteric modulators for A1 adenosine receptors.
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means no dissociation and a score of zero complete dissociation [23].
Nikolakopoulos et al. studied 2-aminothiophene-3-carboxylates and
carboxamides as adenosine A1 receptor allosteric enhancers. Com-
pound 20 was more potent and efﬁcacious than PD 81,723 (Fig. 2).
PD81,723 had an AE score of 28%, while for compound 20 it was 79.5%
[24]. Interestingly, 2-aminoselenophene-3-carboxylates also proved
to be allosteric enhancers of A1 adenosine receptors. Compound 21
had an AE score of 64% and it was signiﬁcantly more potent as an
allosteric enhancer of A1 adenosine receptor than its thiophene
analogue. However it is noteworthy, that this compound is not stable
under mildly acidic conditions [25].
Aurelio et al. synthesized two more series of 5-substituted 2-
aminothiophenes. In the 3-benzoyl series a 5-phenyl group was found
to give the greatest potency (22: ED50=2.1 μM, AE score=18%)
(Fig. 3). However the analogue with no 5-substituent (23:
ED50=15.8 μM, AE score=77%) proved to be the most efﬁcacious.
In the 3-ethoxycarbonyl series, the 5-(4-chlorophenyl) analogue was
the most potent and efﬁcacious (24: ED50=6.6 μM, AE score=57%)
[26]. The same research group also studied a variety of 4-substituted2-amino-3-benzoylthiophenes, among which were further potent
functional allosteric enhancers of the A1 adenosine receptor [27].
The ﬁrst radiolabelled adenosine A1 allosteric enhancer, the tritiated
form of compound 2, was prepared by Romagnoli et al. (Fig. 2). The
biological investigation of this compound, [3H]T-62, suggested the
presence of an allosteric binding site on the adenosine A1 receptor
distinct fromtheorthosteric binding site for agonists andantagonists [28].
In a pharmacophore-based library screen ethyl 5-amino-3-(4-tert-
butylphenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxylate
was identiﬁed as a new allosteric modulator of the adenosine A1
receptor. On the basis of this lead compound, various derivatives were
prepared and evaluated for activity at the humanA1 adenosine receptor.
However these compounds turned out to be a new class of hA1
adenosine receptor antagonists that can also recognize the receptor's
allosteric sitewith lower potency. Among them compound25proved to
be the most potent [29]. Similar results were found for a series of 2-
amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines, e.g. compound 26 for
which theAE scorewas82.9% [30]. Theseﬁndings allow to conclude that
changes in orthosteric ligand dissociation kinetics by a test compound
cannot guarantee that the predominant pharmacological effect will be
Fig. 4. 2-Aminothiazoles and [1,2,4]thiadiazole analogues as putative allosteric modulators for A1 adenosine receptors.
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terically at the hA1 adenosine receptor often have close structural
resemblance, which suggests that the allosteric site on the A1 adenosine
receptor is closer or more similar to the orthosteric site on the A1
adenosine receptor than in other Class A GPCRs.
2-Aminothiazoles are representatives of another chemical class of
allosteric enhancers of agonist binding at cloned hA1 adenosine
receptors. The most potent and efﬁcacious enhancer of this series was
compound 27 (Fig. 4). Its potency wasmentioned to be 127 times that
of PD 81,723 (EC50 values 0.3 and 38 μM, respectively). The intrinsic
activity of compound 27 was twice that of PD 81,723. The enhancing
effect at A2A adenosine receptors and A3 adenosine receptors by this
compound was found to be weak [31].
We also prepared a number of 2-aminothiazoles and their amide
derivatives. The 2-aminothiazoles (the free bases) were tested as
allosteric enhancers of agonist binding to human adenosine A1 receptors.
The compounds did not show any such effect, in contrast to the above
ﬁndings of Chordia et al. [31]. Some of the amides proved to be
moderately active antagonists on human adenosine A1 and/or A2A
receptors with lower or negligible potency at adenosine A3 receptors
[32]. Chordia et al. investigated these contrastingﬁndings ina subsequent
study. They found that the free bases of this type of compounds in fresh
solutions are only weak allosteric enhancers. However, the allosteric
enhancing activity in solutions of these compounds in DMF, DMSO or
acetonitrile increased after 4 h and ﬁnally led to a constant activity
equivalent to that of the hydroiodide salts after 12 h [33].
SCH-202676 (N-(2,3-diphenyl-[1,2,4]thiadiazole-5(2H)-ylidene)
methanamine) was reported to act as a more promiscuous agent
(Fig. 4). It appeared to modulate the activity of many GPCRs, including
opioid, muscarinic, adrenergic and dopaminergic receptors [34]. We
synthesized anumber of 2,3,5-substituted [1,2,4]thiadiazole analogues of
SCH-202676 and tested these as potential allosteric modulators of
adenosine receptors. SCH-202676 showed a mixed behaviour on
adenosine receptors. It displaced agonist binding to A1 receptors in a
reversible manner and both agonist and antagonist binding to A2A
receptors. The displacement curves were very steep, unlike normal
competitive displacement curves. On A1 adenosine receptors compound
28 was shown to be an allosteric enhancer of antagonist ([3H]DPCPX)
binding (Fig. 4) [35].
We also investigated a new series of 2,3,5-substituted [1,2,4]
thiadiazoles. Results of radioligand binding experiments and stability
studies by HPLC and HPLC-MS showed that the compounds are highlyFig. 5. Amiloride derivatives as allostericreactive sulfhydryl modifying agents rather than allosteric inhibitors.
They are reduced into their thiourea precursors by thiol groups of e.g.,
cysteine residues in proteins. This general feature most probably
explains their overall lack of selectivity [36].
Amiloride (a diuretic drug) is also acting as a promiscuous agent. It
interacts with many GPCRs such as α2-adrenergic receptors [37].
Amiloride also interacts with the A1 adenosine receptor at a site
distinct from the orthosteric ligand binding site. Pharmacologically,
amiloride behaved as an A1 receptor antagonist with binding
characteristics that differ from the classic A1 receptor antagonists
such as DPCPX. Amiloride and 5-(N,N-dimethyl)amiloride (DMA) are
more potent at A1 receptors than at A3 receptors (Fig. 5) [38–40].
1.2. A2A adenosine receptors
Amiloride and analogues were demonstrated to be allosteric
inhibitors for the A2A adenosine receptor too. Among the derivatives
tested HMA proved to be the most potent allosteric inhibitor (Fig. 5).
Amiloride analogues increased the dissociation rate of the antagonist
[3H]ZM 241385 from the A2A adenosine receptor, however they did
not show any effect on the dissociation rate of the agonist [3H]
CGS21680 [41]. Sodium ions (high concentrations of NaCl) rather
decreased the dissociation rate of the antagonist [3H]ZM241385 from
the A2A adenosine receptor in a concentration-dependent manner.
Recently, 1-[4-(9-benzyl-2-phenyl-9H-purin-6-ylamino)-phenyl]-
3-phenyl-urea derivatives and 1-[4-(9-benzyl-2-phenyl-9H-8-aza-
purin-6-ylamino)-phenyl]-3-phenyl-urea derivatives have been stud-
ied by Giorgi et al. Compound 29 proved to be an allosteric enhancer on
the A2A receptor (see Fig. 6). In the equilibrium displacement studies
both [3H]ZM241385 and [3H]CGS21680 were used; 29 at 10 μM
increased the speciﬁc binding of the two radioligands. In a kinetic
dissociation study this compound slowed the dissociation of [3H]
ZM241385 from the adenosine A2A receptor, while a similar experiment
on the agonist radioligand was not reported [42]. In a functional study
on rat aortic rings 29 shifted the dose–response curve of CGS21680
signiﬁcantly to the left. This compound may serve as a lead for
developing other allosteric modulators for the A2A adenosine receptor.
1.3. A2B adenosine receptors
Allosteric modulators for A2B adenosine receptors have not been
reported yet. Until recently, there was no suitable radioligand for thismodulators of adenosine receptors.
Fig. 6. Allosteric modulator of A2A adenosine receptors.
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However, with the advent of the radiolabeled antagonist [3H]
MRS1754 and other radioligands such as [3H]PSB603 [43] these
studies are now feasible. A radiolabeled agonist is not available,
however, therefore identiﬁcation of allosteric enhancers of agonist
binding is still hampered.
1.4. A3 adenosine receptors
Amiloride analogues are also allosteric inhibitors of antagonist
binding at A3 adenosine receptor subtypes [40]. HMA is more potent
at A3 receptors than on A1 adenosine receptors (Fig. 5).
The ﬁrst selective allosteric enhancers of agonist binding at the
human A3 adenosine receptor were reported by Gao et al. [44]. The
effects of the reference A3 receptor agonist Cl-IB-MECA on forskolin-
induced cAMP formationwere signiﬁcantly enhanced by several 3-(2-
pyridinyl)isoquinoline derivatives, previously identiﬁed as potential
antagonists for the human A3 adenosine receptor [45]. VUF5455 (see
Fig. 7) was shown to be selective for the agonistic state of the A3
adenosine receptors. In competitive binding studies on cloned human
A3 adenosine receptors VUF5455 displayed modest afﬁnity as an
orthosteric antagonist (Ki=1680 nM). Replacement of the 7-methyl
group of VUF5455 by H (VUF8504) had no inﬂuence on the allostericFig. 7. Structures of allosteric modulactivity but increased the A3 adenosine receptor afﬁnity nearly 100-
fold (Ki=17.3 nM). Exchanging the 4′-methoxy group of VUF8504 by
methyl (VUF8502) or H (VUF8507) lowered the A3 adenosine
receptor afﬁnity (Ki values of 96 and 204 nM) without affecting the
allosteric activity. The corresponding imino instead of carboxamido
analogues displayed moderate A3 receptor afﬁnity (Ki values 300–
700 nM), but did not have allosteric properties. Thus, although
VUF5455 is not devoid of A3 adenosine receptor antagonistic activity,
the compoundmight be used as a lead for the design of pure allosteric
enhancers of A3 adenosine receptors.
1H-imidazo-[4,5-c]quinolines had been identiﬁed as non-xanthine
adenosine receptor antagonists, predominantly active on the adenosine
A1 receptor [46]. Later, this type of compoundswere shown to represent
a second series of allosteric modulators for the A3 adenosine receptor.
Among these compounds DU124183 (see Fig. 7) selectively enhanced
agonist binding and function at A3 adenosine receptors, similar to
VUF5455. However, in contrast to VUF5455, DU124183 increased also
the maximum efﬁcacy of A3 adenosine receptor agonists in the cAMP
assaywith clonedhumanA3 adenosine receptors. Thiswas evident from
themarked leftward shift of the concentration–response curve of the A3
adenosine receptor agonists in the presence of an orthosteric antagonist
and a potentiation of the maximum agonist efﬁcacy by approximately
30%. In radioligand displacement studies, DU124183 also dis-
played some orthosteric activity as it bound with moderate afﬁnity
(Ki=820 nM) to human A3 adenosine receptors [46,47].
The aim of a subsequent study was the optimization of DU124183
(Fig. 7). Structural modiﬁcations were made at the 4-amino and 2-
positions of themolecule, partly using the Topliss scheme for aromatic
substitution [48]. The compounds were tested in binding and
functional assays [49]. Two compounds, 2-cyclopentyl-4-benzyla-
mino and 2-cyclohexyl-4-(3,4-dichlorophenyl)amino (LUF6000, see
Fig. 7)) analogues stood out; they potentiated the maximum efﬁcacy
of the agonist Cl-IB-MECA by 45–50%. Moreover LUF6000 enhanced
agonist efﬁcacy in a functional assay and decreased the agonist
dissociation rate without inﬂuencing agonist potency. Most allosteric
enhancers in this study only modestly inhibited orthosteric ligand
binding, if at all. It was concluded that structural requirements for
allosteric enhancement at the A3 adenosine receptor are distinct from
those for the inhibition of equilibrium radioligand binding. A further
series of 2- and 4-substituted 1H-imidazo[4,5-c]quinoline-4-amineators of A3 adenosine receptors.
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Compound 30 was endowed with activity as an allosteric enhancer
comparable to that of LUF6000. Compound 30 showed minimal
inhibition of orthosteric adenosine receptor binding [50]. In a separate
study LUF6000 was found to be an allosteric enhancer of the maximal
effect exerted by structurally diverse agonists at the adenosine A3
receptor, being more effective for low-efﬁcacy than for high-efﬁcacy
agonists. LUF6000 was even capable of converting an antagonist into
an agonist for this receptor subtype [51].
The aimofHeitman et al. [52]was toﬁndanewchemical template as
the basis for novel allosteric modulators of the adenosine A3 receptor
with negligible orthosteric effects and selectivity over the A1 receptor.
LUF6000 was the reference compound. Scission of the chemical bond in
the structure led to a series of 2,4-disubstituted quinolines as allosteric
enhancers of the adenosine A3 receptor. The newly synthesized
compounds and the reference compound LUF6000 were tested in
equilibrium displacement assays, which were performed with 125I-AB-
MECA on CHO cells expressing the human A1 or A3 receptor, and in
kinetic radioligand binding assays. Their effect on [3H]ZM241385 and
[3H]MRS1754 equilibrium binding at the adenosine A2A and A2B
receptors was also examined (Table 1). Most compounds moderately
inhibited radioligand binding to the adenosine A1 or A3 receptor at
10 μM, except for compounds32 and 39 that showedmarked inhibition.
Compound 39 also inhibited radioligand binding at both the adenosine
A2A and A2B receptor. The effect of the compounds on the dissociation
rate of 125I-AB-MECA from the receptor was investigated, as a measure
for allosterism. Compounds with a cyclopentyl substituent at the R1
position (31–33) decreased the dissociation rate of 125I-AB-MECA from
the adenosine A3 receptor. The dissociation rate from the adenosine A1
receptorwas not inﬂuenced. Themost potent allosteric enhancerwith a
cyclopentyl substituent at R1 was obtained in combination with a 3,4-
dichlorophenyl group at R2 (31). For compounds 35 and 36 (LUF6096)
the cyclohexyl group at R1 and the substituted phenyl group at R2
resulted in a strongly increased potency. A 4-methylphenyl (37) and an
indane (38) substituent also resulted in highly potent allostericTable 1
Afﬁnity and modulatory potency of compounds 31–39 and that of LUF6000 at the human
enhancement at 10 μM.a
No. % Displacementb
R1 R2 hA1
31 CP 3,4-Cl2-Ph 17
32 CP CP 80
33 CP 61
34 CB 3,4-Cl2-Ph 22
35 CH Ph 17
36 CH 3,4-Cl2-Ph 12
37 CH 4-Me-Ph 63
38 CH 20
39 Ph 73
LUF 6000 39
aAll experiments were performed using CHO cells stably transfected with the human adenos
A2A receptor.
bDisplacementof speciﬁc 125I-AB-MECA(A1 andA3), [3H]ZM241385 (A2A), or [3H]MRS1754(A2B)b
cDissociation of 125I-AB-MECA induced by an excess DPCPX (A1) or Cl-IB-MECA (A3) in the a
determined after 90 (A1) or 120 min (A3) of dissociation, where the control was set at 100enhancers. Thus the cyclohexyl group ar R1 yielded compounds with
higher potency than the ones with a cyclopentyl group. Compound 36
(LUF6096) was the most potent enhancer of these series and showed
thehighest structural similarity to LUF6000. Furthermore, compound36
(LUF6096) showed a decreased, almost negligible, orthosteric effect on
the adenosine A1 and A3 receptors when compared to LUF6000.
Lane et al. [53] investigated the effect of a different type of
compounds, cannabinoid ligands, on the human adenosine A3
receptor. Interestingly, 2-arachidonylglycerol (2-AG) was able to
inhibit agonist [125I]-AB-MECA binding at the human A3 adenosine
receptor. In the presence of 2-AG, the rate of [125I]-AB-MECA
dissociation was increased, suggesting that 2-AG acts as a negative
allosteric modulator (allosteric inhibitor) of the hA3 adenosine
receptor. Since the human A3 adenosine receptor is expressed in
astrocytes and microglia, these ﬁndings may be relevant in cerebral
ischemia, a pathological condition in which levels of 2-AG are raised.
1.5. Mutagenesis studies, binding sites for allosteric modulators
It is important to know where the binding sites are for allosteric
modulators on adenosine receptors. Several articles have been
published with some hints on this topic. Bhattacharya et al. provided
evidence that PD 81,723 binds to the A1 adenosine receptor and that it
stabilizes the high-afﬁnity conformational state of the A1 adenosine
receptor-G-protein complex [54].
Site-directed mutagenesis may elucidate the role of amino acids
within the receptor. Mutant A1 adenosine receptors have been
investigated, where glycine at position 14 had been changed into
threonine (G14T). The G14Tmutantmakes the receptor constitutively
active with (very) high agonist afﬁnity. Interestingly on this receptor
PD 81,723 lost its enhancing activity. Apparently, the G14T receptor is
‘locked’ in an active state and as such it does not reveal the site of PD
81,723 binding [55]. Mutation of a threonine residue to alanine at
position 277 (TM7) in the human adenosine A1 receptor strongly
decreased agonist binding to the receptor, but also abolished theadenosine A1, A2A, A2B and A3 receptor subtypes, expressed as % displacement and %
% Enhancementc
hA2A hA2B hA3 hA1 hA3
26 −74 50 125 169
42 72 14 107 114
52 56 90 72 102
41 38 51 72 149
21 5 26 70 210
12 −19 17 94 249
−3 −3 64 121 220
10 19 42 118 217
92 95 60 68 100
3 16 41 120 229
ine A1, A2B or A3 receptor or HEK293 cells stably transfected with the human adenosine
indingat their respective cellmembranes. CP=cyclopentyl; CB=cyclobutyl; CH=cyclohexyl.
bsence (control) and presence of modulator. Enhancement of radioligand binding was
%. Values are the mean of two separate assays performed in duplicate.
Fig. 8. The location of amino acid residues involved in allosteric modulation of A1, A2A and A3 adenosine receptors as displayed in the crystal structure of the adenosine A2A receptor
(side and top view) co-crystallized with its ligand ZM241,385 (PDB coordinates: 3eml) [59]. C-α atoms at these locations are shown as spheres. The position of D55 in the A1
adenosine receptor is equivalent to D58 in the A3 adenosine receptor.
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G14 or T277 form part of the PD 81,723 binding site.
A largely conserved aspartic acid residue in TM2 of the A1
adenosine receptor to alanine (D55A) was mutated by Barbhaiya et
al. This residue was found to play a critical role in allosteric regulation
of ligand—A1 adenosine receptor binding by sodium ions [57]. The
effect of PD81,723 on this mutation has not been investigated.
Gao et al. carried out mutagenesis experiments on the A2A
receptor, where a glutamic acid residue in TM1 and a histidine
residue in TM7 were mutated to glutamine (E13Q) and tyrosine
(H278Y), respectively. The authors concluded the two closely linked
residues Glu13 and His278 in the A2A adenosine receptor are the most
important for agonist recognition and partly responsible for the
allosteric regulation by sodium ions [41,58].
Gao et al. also identiﬁed residues responsible for the allosteric
modulation of the human A3 adenosine receptor. A number of
residues in the transmembrane helical domains were shown to be
involved in the recognition of the allosteric modulators. The F182A
(TM5) and N274A (TM7) mutations impeded the allosteric effects ofFig. 9. A: Structure of hybrid ortho/allosteric molecules (LUF6258, n=9). B: Putative bind
receptor (model based on the crystal structure of the adenosine A2A receptor, see also Fig 8the two modulators DU124183 and VUF5455, but had hardly any
effect on agonist binding, as was the case for N30A (TM1) and D58N
(TM2). The D107N (TM3) mutation eliminated the effects of
DU124183, but not of VUF5455 [59].
To summarize, with the help of site-directed mutagenesis studies,
amino acids involved in allosteric ligand–receptor interactions can be
found. Experiments have been carried out on A1, A2A and A3 receptors,
while A2B receptors have not been studied yet. Asp55 in TM2 is
probably responsible for allosteric regulation of binding by sodium
ions and amilorides for A1 adenosine receptors, whereas the G14T
(TM1) and T277A (TM7) mutations cause PD 81,723 to lose its
enhancing activity. For A2A adenosine receptors Glu13 in TM1 and
His278 in TM7 have been shown to be linked to allosteric regulation
by sodium ions. For A3 adenosine receptors the two modulators
DU124183 and VUF5455 lost their allosteric effects upon F182A
(TM5) and N274A (TM7) mutation. The D107N (TM3) mutation
eliminated the effects of DU124183, but not of VUF5455. The residues
studied only yield a partial view of the amino acids involved in the
allosteric regulation of adenosine receptors. The location of theing site model of such hybrid molecules extending to the extracellular domains of the
).
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model, based on the recently reported crystal structure of the
adenosine A2A receptor [60] (Fig. 8).
1.6. Hybrid ortho/allosteric ligands
In a different, medicinal chemistry-driven approach we recently
synthesized a series of bivalent ligands with an increasing linker length
between the orthosteric and allosteric pharmacophores and used these
as tools to search for the allosteric site on the A1AR [61]. The compounds
were tested in both equilibrium radioligand displacement and func-
tional assays in the absence and presence of PD81,723. Bivalent ligand
N6-[2-amino-3-(3,4-dichlorobenzoyl)-4,5,6,7-tetrahydrothieno[2,3-c]
pyridin-6-yl-9-nonyloxy-4-phenyl]-adenosine (LUF6258) with a 9
carbon atom spacer did not show signiﬁcant changes in afﬁnity or
potency in the presence of PD81,723, indicating that this ligand bridged
both sites on the receptor. From molecular modeling studies it was
suggested that the allosteric site of the A1AR is located in the proximity
of the orthosteric site, possibly within the boundaries of the second
extracellular loop of the receptor (Fig. 9).
1.7. Therapeutic signiﬁcance
Most of the studies described so far focused on in vitro assay
systems, often with recombinant receptors. The translation towards
the clinic has been modest so far; currently, there are no clinical trials
of allosteric modulators for adenosine receptors running or recruiting
(see www.clinicaltrials.gov, accessed June 2010). From adenosine's
role in (patho)physiology one may well speculate about the potential
use of allosteric enhancers of adenosine's actions in disease, such as
(cardio)vascular problems (A1, A3; arrhythmias, ischemia), diabetes/
lipolysis (A1), cancer, auto-immune diseases and chronic inﬂamma-
tory conditions (A3).
A few in vivo studies, in which allosteric enhancers were used,
have been reported for the adenosine A1 receptor, but not for the
adenosine A3 receptor. CNS administration of either LUF5484 (3) or
PD 81,723 through a microdialysis probe in rats caused a concentra-
tion-dependent increase of extracellular acetylcholine levels of
approximately 40% [62]. Treating dogs with PD 81,723 by intracor-
onary infusion reduced the time required for ischemia to produce
preconditioning [63]. In various rat models of both neuropathic [64]
and inﬂammatory pain [65] or hypersensitivity after surgery [66] T-62
(2) proved efﬁcacious. The compound has been reported to undergo
clinical evaluation in patients with postherpetic neuralgia experienc-
ing pain [67].
2. Conclusions
Allosteric modulators of GPCR function are promising candidate
drugs. By binding to sites different from the primary one for natural
hormones and neurotransmitters they modulate receptor conforma-
tions in the presence of an orthosteric ligand. Although an allosteric
modulator may not possess efﬁcacy by itself, it can provide a powerful
therapeutic advantage over orthosteric ligands, as they selectively
inﬂuence tissue responses only when the endogenous agonist is
present. With respect to adenosine receptors allosteric enhancers for
adenosine A1 and for adenosine A3 receptors have been most studied.
It appears now possible to almost fully separate orthosteric from
allosteric activity, a condition that was only recently met.
Acknowledgements
The authors thank Carmen Klein Herenbrink for her expert help
with Fig. 8. Financial support from the Dutch Top Institute Pharma
(project number D1-105) is gratefully acknowledged.References
[1] B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, K.N. Klotz, J. Linden, International
Union of Pharmacology: XXV. Nomenclature and classiﬁcation of adenosine
receptors, Pharmacol. Rev. 53 (2001) 527–552.
[2] T.W. Schwartz, B. Holst, Allosteric enhancers, allosteric agonists and ago-allosteric
modulators: where do they bind and how do they act? Trends Pharmacol. Sci. 28
(2007) 366–373.
[3] W. Soudijn, I. van Wijngaarden, A.P. IJzerman, Allosteric modulation of G protein-
coupled receptors: perspectives and recent developments, Drug Discov. Today 9
(2004) 752–758.
[4] W. Soudijn, I. van Wijngaarden, A.P. IJzerman, Allosteric modulation of G protein-
coupled receptors, Curr. Opin. Drug Discov. Dev. 5 (2002) 749–755.
[5] L.T. May, K. Leach, P.M. Sexton, A. Christopoulos, Allosteric modulation of G
protein-coupled receptors, Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1–51.
[6] Z.-G. Gao, K.A. Jacobson, Allosterism in membrane receptors, Drug Discov. Today
11 (2006) 191–202.
[7] J.A. Lewis, E.P. Lebois, C.W. Lindsley, Allosteric modulation of kinases and GPCRs:
design principles and structural diversity, Curr. Opin. Chem. Biol. 12 (2008)
269–280.
[8] K.A. Jacobson, Z.-G. Gao, Adenosine receptors as therapeutic targets, Nat. Rev.
Drug Discov. 5 (2006) 247–264.
[9] Z.-G. Gao, S.-K. Kim, A.P. IJzerman, K.A. Jacobson, Allosteric modulation of the
adenosine family of receptors, Mini Rev. Med. Chem. 5 (2005) 545–553.
[10] P.G. Baraldi, M.A. Iaconinoto, A.R. Moorman, M.D. Carrion, C.L. Cara, D. Preti, O.C.
Lopez, F. Fruttarolo, M.A. Tabrizi, R. Romagnoli, Allosteric enhancers for A1
adenosine receptor, Mini Rev. Med. Chem. 7 (2007) 559–569.
[11] A. Göblyös, A.P. IJzerman, Allostericmodulation of adenosine receptors, Purinergic
Signal. 5 (2009) 51–61.
[12] R.F. Bruns, J.H. Fergus, L.L. Coughenour, G.G. Courtland, T.A. Pugsley, J.H. Dodd, F.J.
Tinney, Structure–activity relationships for enhancement of adenosine A1 receptor
binding by 2-amino-3-benzoylthiophenes, Mol. Pharmacol. 38 (1990) 950–958.
[13] R.F. Bruns, J.H. Fergus, Allosteric enhancement of adenosine A1 receptor binding and
function by 2-amino-3-benzoylthiophenes, Mol. Pharmacol. 38 (1990) 939–949.
[14] F.J. Tinney, J.P. Sanchez, J.A. Nogas, Synthesis and pharmacological evaluation of 2,
3-dihydro-1H-thieno[2, 3-e][1, 4]diazepines, J. Med. Chem. 17 (1974) 624–630.
[15] P.A.M. van der Klein, A.P. Kourounakis, A.P. IJzerman, Allosteric modulation of the
adenosine A1 receptor: synthesis and biological evaluation of novel 2-amino-3-
benzoylthiophenes as allosteric enhancers of agonist binding, J. Med. Chem. 42
(1999) 3629–3635.
[16] A.P. Kourounakis, P.A.M. van de Klein, A.P. IJzerman, Elucidation of stucture–
activity relationships of 2-amino-3-benzoylthiophenes: study of their allosteric
enhanceing vs. antagonistic activity on adenosine A1 receptors, Drug Dev. Res. 49
(2000) 227–237.
[17] P.G. Baraldi, A.N. Zaid, I. Lampronti, F. Fruttarolo, M.G. Pavani, M.A. Tabrizi, J.C.
Shryock, E. Leung, R. Romagnoli, Synthesis and biological effects of a new series of
2-amino-3benzoylthiophenes as allosteric enhancers of A1 adenosine receptor,
Bioorg. Med. Chem. Lett. 10 (2000) 1953–1957.
[18] P.G. Baraldi, R. Romagnoli, M.G. Pavani, M.C. Nunez, M.A. Tabrizi, J.C. Shryock, E.
Leung, A.R. Moorman, C. Uluoglu, V. Iannotta, S. Merighi, P.A. Borea, Synthesis and
biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhan-
cers of the A1 adenosine receptor, J. Med. Chem. 46 (2003) 794–809.
[19] P.G. Baraldi, M.G. Pavani, J.C. Shryock, A.R. Moorman, V. Iannatta, P.A. Borea, R.
Romagnoli, Synthesis of 2-amino-3-heteroaroylthiophenes and evalutaion of
their activity as potential allosteric enhancers at the human A1 receptor, Eur. J.
Med. Chem. 39 (2004) 855–865.
[20] R. Romagnoli, P.G. Baraldi, A.R.Moorman, M.A. Iaconinoto, M.D. Carrion, C.L. Cara, M.
A. Tabrizi, D. Preti, F. Fruttarolo, S.P. Baker, K. Varani, P.A. Borea, Microwave-assisted
synthesis of thieno[2, 3-c]pyridine derivatives as a new series of allosteric enhancers
at the adenosine A1 receptor, Bioorg. Med. Chem. 16 (2006) 5530–5533.
[21] R. Romagnoli, P.G. Baraldi, M.D. Carrion, C.L. Cara, O. Cruz-Lopez, M.A. Iaconinoto,
D. Preti, J.C. Shryock, A.R. Moorman, F. Vincenzi, K. Varani, P.A. Borea, Synthesis
and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted)
piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine
receptor, J. Med. Chem. 51 (2008) 5875–5879.
[22] C.E. Tranberg, A. Zickgraf, B.N. Giunta, H. Lütjens, H. Figler, L.J. Merphree, R. Falke,
H. Fleischer, J. Linden, P.J. Scammells, R.A. Olsson, 2-Amino-3-aroyl-4, 5-
alkylthiopenes: agonist allosteric enhancers at human A1 adenosine receptors,
J. Med. Chem. 45 (2002) 382–389.
[23] H. Lütjens, A. Zickgraf, H. Figler, J. Linden, R.A. Olsson, P.J. Scammells, 2-Amino-3-
benzoylthiophene allosteric enhancers of A1 adenosine agonist binding: new 3-,
4-, and 5-modiﬁcations, J. Med. Chem. 46 (2003) 1870–1877.
[24] G. Nikolakopoulos, H. Figler, J. Linden, P.J. Scammels, 2-Aminothiophene-3-
carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers,
Bioorg. Med. Chem. 14 (2006) 2358–2365.
[25] K.M. Aumann, P.J. Scammels, J.M. White, C.H. Schiesser, On the stability of 2-
aminoselenophene-3-carboxylates: potential dual-acting selenium-containing
allosteric enhancers of A1 adenosine receptor binding, Org. Biomol. Chem. 5
(2007) 1276–1281.
[26] L. Aurelio, H. Figler, B.L. Flynn, J. Linden, P.J. Scammells, 5-Substituted 2-
aminothiophenes as A1 adenosine receptor allosteric enhancers, Bioorg. Med.
Chem. 16 (2008) 1319–1327.
[27] L. Aurelio, C. Valant, B.L. Flynn, P.M. Sexton, A. Christopoulos, P.J. Scammells,
Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacolog-
ical evaluation of 4-substituted 2-amino-3-benzoylthiophenes, J. Med. Chem. 52
(2009) 4543–4547.
1318 A. Göblyös, A.P. IJzerman / Biochimica et Biophysica Acta 1808 (2011) 1309–1318[28] R. Romagnoli, Synthesis and biological characterization of [3H](2-amino-4, 5, 6, 7-
tetrahydrobenzo[b]thiophen-3-yl)-(4-chlorophenyl)-methanone, the ﬁrst radi-
olabelled adenosine A1 allosteric enhancer, Bioorg. Med. Chem. 16 (2006)
1402–1404.
[29] G.N. Ferguson, C. Valant, J. Horne, H. Figler, B.L. Flynn, J. Linden, D.K. Chalmers, P.M.
Sexton,A. Christopoulos, P.J. Scammells, 2-Aminothienopyridazines asnovel adenosine
A1 receptor modulators and antagonists, J. Med. Chem. 51 (2008) 6165–6172.
[30] L. Aurelio, C. Valant, H. Figler, B.L. Flynn, J. Linden, P.M. Sexton, A. Christopoulos, P.
J. Scammells, 3- and 6-Substituted 2-amino-4, 5, 6, 7-tetrahydrothieno[2, 3-c]
pyridines as A1 adenosine receptor allosteric modulators and antagonists, Bioorg.
Med. Chem. 17 (2009) 7353–7361.
[31] M.D. Chordia, L.J. Murphree, T.L. Macdonald, J. Linden, R.A. Olsson, 2-Aminothia-
zoles: a new class of agonist allosteric enhancers of A1 adenosine receptors,
Bioorg. Med. Chem. Lett. 12 (2002) 1563–1566.
[32] A. Göblyös, S.N. Santiago, D. Pietra, T. Mulder-Krieger, J. von Frijtag Drabbe
Künzel, J. Brussee, A.P. IJzerman, Synthesis and biological evaluation of 2-
aminothiazoles and their amide derivatives on human adenosine receptors. Lack
of effect of 2-aminothiazoles as allosteric enhancers, Bioorg. Med. Chem. 13
(2005) 2079–2087.
[33] M.D. Chordia, M. Zigler, L.J. Murphree, H. Figler, T.L. Macdonald, R.A. Olsson, J.
Linden, 6-Aryl-8H-indeno[1, 2-d]thiazol-2-ylamines: A1 adenosine receptor agonist
allosteric enhancers having improved potency, J. Med. Chem. 48 (2005) 5131–5139.
[34] A.B. Fawzi, D. Macdonald, L.L. Benbow, A. Smith-Torhan, H. Zhang, B.C. Weig, G.
Ho, D. Tulshian, M.E. Linder, M.P. Graziano, SCH-202676: an allosteric modulator
of both agonist and antagonist binding to G protein-coupled receptors, Mol.
Pharmacol. 59 (2001) 30–37.
[35] A.M.C.H. van den Nieuwendijk, D. Pietra, L. Heitman, A. Göblyös, A.P. IJzerman,
Synthesis and biological evaluation of 2, 3, 5-substituted [1, 2, 4]thiadiazoles as
allosteric modulators of adenosine receptors, J. Med. Chem. 47 (2004) 663–672.
[36] A. Göblyös, H. de Vries, J. Brussee, A.P. IJzerman, Synthesis and biological
evaluation of a new series of 2, 3, 5-substituted [1, 2, 4]thiadiazoles as modulators
of adenosine A1 receptors and their molecular mechanism of action, J. Med. Chem.
48 (2005) 1145–1151.
[37] D.A. Horstman, S. Brandon, A.L. Wilson, C.A. Guyer, E.J. Cragoe, L.E. Limbrid, An
aspartate conserved among G-protein receptors confers allosteric regulation of
α2-adrenergic receptors by sodium, J. Biol. Chem. 265 (1990) 21590–21595.
[38] A. Garritsen, A.P. IJzerman, M.W. Beukers, E.J. Cragoe Jr., W. Soudijn, Interaction of
amiloride and its analogues with adenosine A1 receptors in calf brain, Biochem.
Pharmacol. 40 (1990) 827–834.
[39] A. Garritsen, A.P. IJzerman, M.W. Beukers, W. Soudijn, Chemical modiﬁcation of
adenosine A1 receptors. Implications for the interaction with R-PIA, DPCPX and
amiloride, Biochem. Pharmacol. 40 (1990) 835–842.
[40] Z.-G. Gao, N. Melman, A. Erdmann, S.G. Kim, C.E. Müller, A.P. IJzerman, K.A.
Jacobson, Differential allosteric modulation by amiloride analogues of agonist and
antagonist binding at A1 and A3 adenosine receptors, Biochem. Pharmacol. 65
(2003) 525–534.
[41] Z.-G. Gao, A.P. IJzerman, Allosteric modulation of A2A adenosine receptors by
amiloride analogues and sodium ions, Biochem. Pharmacol. 60 (2000) 669–676.
[42] I. Giorgi, G. Biagi, A.M. Bianucci, A. Borghini, O. Livi, M. Leonardi, D. Pietra, V.
Calderone, A. Martelli, N6-1, 3-Diphenylurea derivatives of 2-phenyl-9-
benzyladenines and 8-azaadenines: synthesis and biological evaluation as
allosteric modulators of A2A adenosine receptors, Eur. J. Med. Chem. 43 (2008)
1639–1647.
[43] T. Borrmann, S.Hinz,D.C. Bertarelli,W. Li, N.C. Florin, A.B. Scheiff, C.E.Müller, 1-Alkyl-
8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of
adenosine A2B receptor antagonists and a new radioligand with subnanomolar
afﬁnity and subtype speciﬁcity, J. Med. Chem. 52 (2009) 3994–4006.
[44] Z.-G. Gao, J.E. van Muijlwijk-Koezen, A. Chen, C.E. Müller, A.P. IJzerman, K.A.
Jacobson, Allosteric modulation of A3 adenosine receptors by a series of 3-(2-
pyridinyl)isoquinoline derivatives, Mol. Pharmacol. 60 (2001) 1057–1063.
[45] J.E. van Muijlwijk-Koezen, H. Timmerman, R. Link, H. van der Goot, A.P. IJzerman,
A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline
derivatives, J. Med. Chem. 41 (1998) 3987–3993.
[46] P.J.M. van Galen, P. Nissen, I. van Wijngaargen, A.P. IJzerman, W. Soudijn, 1H-
Imidazo[4, 5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists,
J. Med. Chem. 34 (1991) 1202–1206.
[47] Z.-G. Gao, S.-G. Kim, K.A. Soltysiak, N. Melman, A.P. IJzerman, K.A. Jacobson,
Selective allosteric enhancement of agonist binding and funtion at human A3adenosine receptors by a series of imidazoquinoline derivatives, Mol. Pharmacol.
62 (2002) 81–89.
[48] J.G. Topliss, Utilization of operational schemes for analog synthesis in drug design,
J. Med. Chem. 15 (1972) 1006–1011.
[49] A. Göblyös, Z.-G. Gao, J. Brussee, R. Connestari, S.N. Santiago, K. Ye, A.P. IJzerman, K.A.
Jacobson, Structure–activity relationships of new 1H-imidazo[4, 5-c]quinolin-4-
amine derivatives as allosteric enhancers of theA3 adenosine receptor, J.Med. Chem.
49 (2006) 3354–3361.
[50] Y. Kim, S. de Castro, Z.-G. Gao, A.P. IJzerman, K.A. Jacobson, Novel 2- and 4-
substituted 1H-Imidazo[4, 5-c]quinolin-4-amine derivatives as allosteric mod-
ulators of the A3 adenosine receptor, J. Med. Chem. 52 (2009) 2098–2108.
[51] Z.-G. Gao, K. Ye, A. Göblyös, A.P. IJzerman, K.A. Jacobson, Flexible modulation of
agonist efﬁcacy at the human A3 adenosine receptor by an imidazoquinoline
allosteric enhancer LUF6000, BMC Pharmacol. 8 (2008) 20–30.
[52] L.H. Heitman, A. Göblyös, A.M. Zweemer, R. Bakker, T. Mulder-Krieger, J.P.D. van
Veldhoven, H. de Vries, J. Brussee, A.P. IJzerman, A series of 2, 4-disubstituted
quinolines as a new class of allosteric enhancers of the adenosine A3 receptor,
J. Med. Chem. 52 (2009) 926–931.
[53] J.R. Lane, M.W. Beukers, T. Mulder-Krieger, A.P. IJzerman, The endocannabinoid 2-
arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine
receptor, Biochem. Pharmacol. 79 (2010) 48–56.
[54] S. Bhattacharya, R.L. Youkey, K. Ghartey, M. Leonard, J. Linden, A.L. Tucker, The
allosteric enhancer PD 81, 723 increases chimaeric A1/A2A adenosine receptor
coupling with Gs, Biochem. J. 396 (2006) 139–146.
[55] R.A.F. Ligt, S.A. Rivkees, A. Lorenzen, R. Leurs, A.P. IJzerman, A “locked-on”,
constitutively active mutant of the adenosine A1 receptor, Eur. J. Pharmacol. 510
(2005) 1–8.
[56] A. Kourounakis, C. Visser, M. de Groote, A.P. IJzerman, Differential effects of the
allosteric enhancer (2-amino-4, 5-dimethyl-trienyl)[3-(triﬂuoromethyl)phenyl]-
methanone (PD 81, 723) on agonist and antagonist binding and function at the
human wild-type and a mutant (T277A) adenosine A1 receptor, Biochem.
Pharmacol. 61 (2001) 137–144.
[57] H. Barbhaiya, R. McClain, A. IJzerman, S.A. Rivkees, Site-directed mutagenesis of
the human A1 adenosine receptor: inﬂuences of acidic and hydroxy residues in
the ﬁrst four transmembrane domains on ligand binding, Mol. Pharmacol. 50
(1996) 1635–1642.
[58] Z.-G. Gao, Q. Jiang, K.A. Jacobson, A.P. IJzerman, Site-directed mutagenesis
studies of human A2A adenosine receptors: involvemement of Glu(13) and His
(278) in ligand binding and sodium modulation, Biochem. Pharmacol. 60 (2000)
661–668.
[59] Z.-G. Gao, S.-K. Kim, A.S. Gross, A. Chen, J.B. Blaustein, K.A. Jacobson, Identiﬁcation
of essential residues involved in the allosteric modulation of the human A3
adenosine receptor, Mol. Pharmacol. 63 (2003) 1021–1031.
[60] V.P. Jaakola, M.T. Grifﬁth, M.A. Hanson, V. Cherezov, E.Y. Chien, J.R. Lane, A.P.
IJzerman, R.C. Stevens, The 2.6 angstrom crystal structure of a human A2A
adenosine receptor bound to an antagonist, Science 322 (2008) 1211–1217.
[61] R. Narlawar, J.R. Lane, M. Doddareddy, J. Lin, J. Brussee, A.P. IJzerman, Hybrid
ortho/allosteric ligands for the adenosine A1 receptor, J. Med. Chem. 53 (2010)
3028–3037.
[62] T.J.H. Bueters, H.P.M. Helden, M. Danhof, A.P. IJzerman, Effects of the adenosine A1
receptor allosteric modulators PD 81, 723 and LUF5484 on the striatal
acetylcholine release, Eur. J. Pharmacol. 454 (2002) 177–182.
[63] T. Mizumura, J.A. Auchampach, J. Linden, R.F. Bruns, G.J. Gross, PD 81, 723, an
allosteric enhancer of the A1 adenosine receptor, lowers the threshold for
ischemic preconditioning in dogs, Circ. Res. 79 (1996) 415–423.
[64] X. Li, D. Conklin, W. Ma, X. Zhu, J.C. Eisenach, Spinal noradrenergic activation
mediates allodynia reduction from an allosteric adenosine modulator in a rat
model of neuropathic pain, Pain 97 (2002) 117–125.
[65] X. Li, D. Conklin, H.-L. Pan, J.C. Eisenach, Allosteric adenosine receptor modulation
reduces hypersensitivity following peripheral inﬂammation by a central mech-
anism, J. Pharmacol. Exp. Ther. 305 (2003) 950–955.
[66] H. Obata, X. Li, J.C. Eisenach, Spinal adenosine receptor activation reduces
hypersensitivity after surgery by a different mechanism than after nerve injury,
Anesthesiology 100 (2004) 1258–1262.
[67] W.F. Kiesman, E. Elzein, J. Zablocki, A1 adenosine receptor antagonists, agonists
and allosteric enhancers, in: C.N. Wilson, S.J. Mustafa (Eds.), Adenosine Receptors
in Health and Disease, Handbook of Experimental Pharmacology, Springer-Verlag,
Berlin Heidelberg, 2009, pp. 25–58.
